RB1 and cancer: Activation of E2Fs has been identified virtually in all human cancers and is commonly accompanied by complex dysfunction of their upstream regulators, like inactivation of RB Transcriptional Corepressor 1 (RB1), overexpression of CDKs, or the invalidation of the CDK inhibitors.9, 10